Press Releases

December 02, 2021
With over 20 years’ experience in infectious disease, oncology, rare and orphan diseases and academia, Dr. McConnell will be responsible for leading the medical affairs function at Venatorx and will oversee the planning and execution of medical strategy, field medical engagement and scientific communications.
November 01, 2021
Venatorx Pharmaceuticals entered into a Research Collaboration and License Agreement with Roche to discover, characterize and develop new small molecule inhibitors of the Penicillin Binding Proteins (“PBPs”) in Gram-negative bacteria focused on agents active against carbapenem-resistant Enterobacterales (CRE).
September 27, 2021
Venatorx Pharmaceuticals, along with its collaborators, will present seven posters and two oral abstracts at IDWeek 2021, which is taking place virtually September 29 – October 3, 2021.

In the News

November 18, 2021
ONE BIG QUESTION: "Do you get the sense that the overall medical community understands the magnitude of the problem of antimicrobial resistance?" ContagionLive marks the start o World Antimicrobials Awareness Week with these insights...
November 17, 2021
Venatorx Pharmaceuticals speaks with ContagionLive about our pipeline, our long-term view for our company, and how the federal government’s use of the nomenclature innovation might actually hinder incremental improvements in antibiotic development.  
October 14, 2021
An improved economic model is needed, one that incentivizes and supports antibiotic innovation and ensures that medicines are available when needed and new drugs are constantly in the pipeline. Venatorx weighs in...

Social Media

Upcoming Events

Saturday, April 23, 2022 - Tuesday, April 26, 2022
Thursday, June 09, 2022 - Monday, June 13, 2022